PATENT CLAIM ANALYSIS

Application Number: 16095370
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["546", "332000"]

Abstract:
Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.

Claim (Index 19):
A method for preventing and/or treating a KCNQ2-5 channel-related disease, characterized by administering an effective amount of the crystal according to  claim 1  to a mammal.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 97.0
- Lexical Diversity: 1.63014
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15671428', '15515243', '16059270', '14424215', '15504514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8142688208732596
- 35 USC 102 Novelty (BERT): 0.5384369708278685
- Combined Prediction Score: 0.7866856358687204
- Mean Citation Score: 355.122582
- Max Citation Score: 389.36298
- Similarity Product: 270.5223508207726

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test